Press release | Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement concerning a dispute relating to a collaboration agreement to discover and commercialize new Nanobodies® which Ablynx and reMYND entered into in 2003.
Ablynx and reMYND settle dispute amicably
reMYND receives a grant of 0.9 million EUR from IWT
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). Visit the IWT website
reMYND receives license renewal from Schering-Plough for RadarScreen
Press release | reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough (NYSE ticker: SGP) for the supply and use of RadarScreen, a novel yeast-based screening system that allows the rapid and cost-effective identification of genotoxic compounds in e
reMYND receives award for Company with an exceptional relevance to society
On September 21st 2009, reMYND received in the Flemish Parliament 'the 1st Award for Company with an exceptional relevance to society' out of the hands of the Flemish minister-president Kris Peeters.
reMYND awarded by the Michael J. Fox Foundation
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation for Parkinson's Research in July 2009.